Medicina clinica
-
Multicenter Study Observational Study
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.
To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. ⋯ There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
-
Multicenter Study
Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r. ⋯ The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors.
-
Multicenter Study Observational Study
Autoimmune haemolytic anaemias: A retrospective study of 93 patients.
Autoimmune haemolytic anaemia (AIHA) is an infrequent and heterogeneous disease in its pathophysiology and clinical behaviour, therefore it is generally managed empirically. ⋯ We found high rates of response to steroids, with very prolonged treatments that cause side effects and corticoid dependence in a third of patients. The combination of steroids with rituximab in the first line, could be indicated in patients with low levels of haemoglobin and serological type IgG+C. The high relapse rates make necessary the development of randomised studies with new drugs or the combination with existing ones, which allow longer response times and with fewer side effects.
-
Multicenter Study
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study.
To analyse the risk of fracture calculated by FRAX® and the frequency of high risk of fracture in the general population in Spain. ⋯ EPISER2016 enabled us to establish the risk of fracture calculated by FRAX® and the prevalence of high risk of fracture in the general population according to the different thresholds used in Spain.
-
Multicenter Study Observational Study
Pharmacological venous thromboembolism prophylaxis in radical prostatectomy.
Pulmonary thromboembolism is one of the most common causes of non-surgical death in patients following urological abdominopelvic surgery. Since the beginning of prophylaxis for venous thromboembolic disease, episodes of deep vein thrombosis and pulmonary thromboembolism have decreased. Our objective is to analyse the prognosis factors of thromboembolic disease, the clinical variability in the use of pharmacological prophylaxis and the results of its application. ⋯ In this study on patients undergoing radical prostatectomy, there was no difference in haemorrhagic complications derived from the use of pharmacological prophylaxis for venous thromboembolic disease. Pharmacological prophylaxis reduces the risk of presenting a thromboembolic event in patients undergoing radical prostatectomy, although this risk is not associated with the approach technique.